In the present study, we have investigated the prevalence of deleterious germline BARD1 variants in a cohort of 4015 patients with clinical suspicion of hereditary breast and/or ovarian cancer, with the aim of elucidating the role of BARD1 in cancer predisposition in the Spanish population. This evidence concerns the gene BARD1 and ovarian cancer.